Semaglutide APIs and Related Intermediates in Different Specifications
Semaglutide is an anti-diabetic drug which is used to treat type 2 diabetes and manage chronic weight. Semaglutide is a glucagon-like peptide-1(GLP-1) receptor agonist with 94% sequence homology with human GLP-1. It increases the production of insulin, which can lower the blood glucose level. Semaglutide also appears to enhance growth of β cells, sites of insulin production, in the pancreas. By lowering appetite and slowing down digestion in the stomach, Semaglutide also can reduce food intake to control body weight.
Semaglutide for injectable grade 99% is prepared for the formulation of Semaglutide injection. The purity of this product can reach 99.0% and the assay should reach 95%~105% with peptide content of Semaglutide 76%~100%.
Semaglutide for oral grade 98% is suitable for the markets with high requirements of oral dose for the control of raw material impurities. The purity of this product should reach 98% with the same acceptance criteria of other standards with Semaglutide injectable grade 99%.
Semaglutide for oral grade 96% is much more suitable for a price sensitive market where the tabbing process does not produce new impurities with its purity of 96%. The assay of this product should reach 90%~100%.
Semaglutide crude product is prepared for the enterprises that have the production capacity and want to own the API approval. Semaglutide API can be obtained after purification by chromatography and freeze drying from Semaglutide crude product. The purity of this product should reach 50% and the assay over 35%.
Semaglutide secondary acylation intermediate is N-1 intermediate of Semaglutide. The protection group of this prodcut was deprotected to obtain Semaglutide crude product, which was purified by chromatography and freeze dried to obtain API. Secondary acylation intermediate is suitable for the enterprises that have the production capacity and want to own the API approval.
|
|
Semaglutide primary acylation intermediate and Semaglutide dipeptide are Semaglutide N-2 main chain intermediate and N-2 fragment. The primary acylation intermediate was acylated with Semaglutide dipeptide to obtain Semaglutide secondary acylation intermediate and further hydrolyzed to obtain Semaglutide crude product. Acylation, hydrolysis tank, high pressure chromatography system, drying equipment are required.
|
|
Semaglutide main chain P29 and Semaglutide side chain (tetrapeptide) are Semaglutide N-3 main chain intermediate and N-3 fragment. TheSemaglutide main chain P29 was acylated with Semaglutide side chain to obtain Semaglutide primary acylation intermediate. Further reaction was underwent to obtain the final API. These products are suitable for for the enterprises that have the production capacity and want to own the API approval. Acylation, hydrolysis tank, high pressure chromatography system, drying equipment are required.
FarmaSino provides these the API with different grade and related intermediates of Semaglutide with reliable quality and competitive price.
Please get more information from following links:
Semaglutide Starts the New Life with Type 2 Diabetes
*All APIs and intermediates for R&D use ONLY.
